First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study

Makoto Maemondo, Yuji Minegishi, Akira Inoue, Kunihiko Kobayashi, Masao Harada, Shoji Okinaga, Naoto Morikawa, Satoshi Oizumi, Tomoaki Tanaka, Hiroshi Isobe, Shoji Kudoh, Koichi Hagiwara, Toshihiro Nukiwa, Akihiko Gemmah

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

INTRODUCTION:: Recent studies have demonstrated that first-line treatment with gefitinib, an epidermal growth factor receptor (EFGR)-targeted tyrosine kinase inhibitor, is significantly superior to standard chemotherapy for advanced non-small-cell lung cancer (NSCLC) harboring EGFR sensitive mutations. Meanwhile, the efficacy of gefitinib therapy among elderly populations diagnosed with EGFR-mutated NSCLC has not yet been elucidated. The purpose of this study was to investigate the efficacy and feasibility of gefitinib for chemotherapy-naive patients aged 75 or older with NSCLC harboring EGFR mutations; generally, these patients have no indication for treatment with platinum doublets. METHODS:: Chemotherapy-naive patients aged 75 years or older with performance status 0 to 1 and advanced NSCLC harboring EGFR mutations, as determined by the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method, were enrolled. The enrolled patients received 250 mg/day of gefitinib orally. RESULTS:: Between January 2008 and May 2009, 31 patients were enrolled, all of whom were eligible. The median age was 80 (range, 75-87) years. Twenty-five patients (81%) were women, and 30 patients (97%) had adenocarcinoma. The overall response rate was 74% (95% confidence interval, 58%-91%), and the disease control rate was 90%. The median progression-free survival was 12.3 months. The common adverse events were rash, diarrhea, and liver dysfunction. One treatment-related death because of interstitial lung disease occurred. CONCLUSIONS:: This is the first study that verified safety and efficacy of first-line treatment with gefitinib in elderly patients having advanced NSCLC with EGFR mutation. Considering its strong antitumor activity and mild toxicity, first-line gefitinib may be preferable to standard chemotherapy for this population.

Original languageEnglish
Pages (from-to)1417-1422
Number of pages6
JournalJournal of Thoracic Oncology
Volume7
Issue number9
DOIs
Publication statusPublished - 2012 Sep

Keywords

  • Epidermal growth factor receptor mutation
  • Gefitinib
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study'. Together they form a unique fingerprint.

  • Cite this

    Maemondo, M., Minegishi, Y., Inoue, A., Kobayashi, K., Harada, M., Okinaga, S., Morikawa, N., Oizumi, S., Tanaka, T., Isobe, H., Kudoh, S., Hagiwara, K., Nukiwa, T., & Gemmah, A. (2012). First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. Journal of Thoracic Oncology, 7(9), 1417-1422. https://doi.org/10.1097/JTO.0b013e318260de8b